AbbVie strikes $10.9 billion deal for Apogee Therapeutics

AbbVie has entered into a definitive agreement to acquire Apogee Therapeutics for nearly $11 billion. This strategic acquisition focuses on Apogee Therapeutics, a company specializing in the development of an experimental drug designed to treat atopic dermatitis. The deal represents a significant investment of $10.9 billion, reflecting a continuing trend of pharmaceutical acquisitions within the industry as AbbVie expands its portfolio through the purchase of this innovative developer of experimental dermatological treatments.